We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Ultrasensitive Test Detects and Serially Monitors Intact Virus Levels in COVID-19 Patients

By LabMedica International staff writers
Posted on 24 Jan 2025
Print article
Image: Clinical workflow and viral detection using the virusHB-Chip (Photo courtesy of Science Advances, DOI:10.1126/sciadv.adh1167)
Image: Clinical workflow and viral detection using the virusHB-Chip (Photo courtesy of Science Advances, DOI:10.1126/sciadv.adh1167)

The ability to isolate and detect whole viruses from complex biofluids could enhance our understanding of how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as other viral infections, spreads within the host, providing valuable insights into their dynamics. Quantifying whole viral particles could inform infectivity and reveal a potential link between viral load and organ damage. Researchers have now found that a method originally created for cancer detection can also identify and track even trace amounts of intact SARS-CoV-2 viral particles in blood and other fluids from patients with acute COVID-19 infections, offering promise for improving future treatment strategies.

In the early days of the pandemic, scientists at Mass General Brigham (Somerville, MA, USA) sought to adapt their cancer vesicle isolation technique to detect SARS-CoV-2 in biofluids like blood, stool, and saliva. They quickly assembled a multidisciplinary team to adapt their technology and expand the potential for detecting intact viruses. Their research, published in Science Advances, demonstrated that this method could detect as few as three viral particles in 1 milliliter of blood. When applied to more than 150 samples (103 plasma, 36 saliva, and 29 stool samples) from COVID-19 patients, the technique accurately measured viral levels over time, with intact viral particles detectable up to 50 days after the initial infection.

“With clinical needs changing, the ability to serially monitor viral load in this manner has great potential for guiding the treatment of patients with long Covid,” said co–senior author Shannon L. Stott, PhD. “This versatile technology could also have widespread applications in viral monitoring for current and future infectious diseases.”

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.